Genprex

Category: Press Releases

Genprex Strengthens Senior Team and Continues to Advance Operations

Genprex announced that it is continuing to grow its senior team with the hiring of Eric Chapdelaine, Senior Director of Pharmaceutical Sciences and Manufacturing, and Kalyn Dabbs, Senior Manager of Communications and Marketing, effective immediately.

Read More

Genprex Appoints John N. Bonfiglio, PhD, to Board of Directors

Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of John N. Bonfiglio, PhD, to the company’s Board of Directors. In recent years, Dr. Bonfiglio served as President and CEO of Oragenics, Inc.

Read More

Genprex to Present at NobleConXV in Fort Lauderdale, Florida

Noble Capital Markets’ Fifteenth Annual Investor / Equity Conference

AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 23, 2019– Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that its President and Chief Operating Officer, Julien Pham, MD, MPH, will deliver a presentation about the company’s unique, leading-edge gene therapies and will also participate in a discussion panel on the topic of “Novel Therapies at the Cutting Edge of Cancer Research” at NobleConXV – Noble Capital Markets’ Fifteenth Annual Investor Conference at the W Hotel in Fort Lauderdale, Florida….

Read More

Genprex to Present at Biotech Showcase™ 2019 in San Francisco

AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 3, 2019– Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most important week in healthcare finance at the Hilton San Francisco Union Square….

Read More

Genprex to Launch Investors Website and Increase Emphasis on Investor Relations in 2019

Company Placing Priority on Investor Engagement with New Website, Email Updates

AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 12, 2018– Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it will be increasing its investor relations efforts in 2019, spearheaded by the launch of an innovative corporate website with more robust investor resources, including the company’s presentations, stock charts and integrated quotes, SEC filings, news, media coverage, and tailored email newsletters, among other advanced communication tools….

Read More

Genprex to Present at the 11th Annual LD Micro Main Event

Presentation Wed., Dec. 5, 2018, at 10:30 a.m. PST

AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 3, 2018– Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that its Chairman and Chief Executive Officer, Rodney Varner, will present at the 11th annual LD Micro Main Event at the Luxe Sunset Boulevard Hotel in Los Angeles, CA….

Read More

Genprex Recognized as Finalist in Technology Innovation Category for Fierce Innovation Awards

AUSTIN, TX, November 29, 2017 – Genprex, Inc., a clinical stage gene therapy company, announced today that is has been selected as a finalist in this year’s Fierce Innovation Awards: Life Sciences Edition brought to you by the publisher of FierceBiotech and FiercePharma. Genprex was recognized as a finalist in the Fierce Technology Innovation Award category….

Read More

Genprex Provides Clinical and Corporate Update for Third Quarter 2018

AUSTIN, Texas–(BUSINESS WIRE)–Nov. 20, 2018– Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update, and the filing of quarterly results for the third quarter ended September 30, 2018 on Form 10-Q with the Securities and Exchange Commission….

Read More

Genprex Appoints Jan Stevens, RN, as Vice President of Clinical Operations

AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 30, 2018– Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of Jan Stevens, RN, as the Company’s Vice President of Clinical Operations. In this role, Ms. Stevens joins the Cambridge office to contribute in supporting various clinical development programs for the Company’s immunogene therapy, Oncoprex™, which is currently being evaluated in clinical and preclinical studies at MD Anderson Cancer Center for the treatment of non-small cell lung cancer (NSCLC)….

Read More

Genprex to Present at Upcoming Investor and Industry Conferences

AUSTIN,Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 1, 2018– Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that the management team will present at the following upcoming investor and industry conferences:

Event: The MicroCap Conference
Date: October 2, 2018
Time: 12:00 PM EDT
Location: New York, NY
Presenter: Rodney Varner, Chairman and CEO

Event: BIO Investor Forum
Date: October 18, 2018
Time: 9:30 AM PDT
Location: San Francisco, CA
Presenter: Dr….

Read More